Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57 results about "Pterin" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pterin is a heterocyclic compound composed of a pteridine ring system, with a "keto group" (a lactam) and an amino group on positions 4 and 2 respectively. It is structurally related to the parent bicyclic heterocycle called pteridine. Pterins, as a group, are compounds related to pterin with additional substituents. Pterin itself is of no biological significance.
Nutraceutical composition and method of use for treatment / prevention of cancer
InactiveUS20070248693A1Function increaseAbility to createBiocideAlgae medical ingredients1,4-BenzoquinonePantothenic acid
The invention describes a pharmaceutical composition and method for treating cancer comprised of A) 2,3-dimethoxy-5-methyl-1,4-benzoquinone and / or B) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least c) one compound capable of maximizing oxidative mitochondrial function preferably riboflavin or vitamin B2 derivatives, FAD, FMN, 5-amino-6-(5′-phosphoribitylamino)uracil, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, niacin, vitamin C and pantothenate and / or d) at least one lactic acid dehydrogenase inhibitor (preferably 2′,3,4′5,7-pentahydroxyflavone) and optionally f) an alkalizing agent (aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium) g) an antiproliferative herb (speranskia or goldenseal) and h) a pharmaceutically acceptable carrier.
Owner:MAZZIO ELIZABETH +1
Pterin analogs
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.
Owner:BIOMARIN PHARMA INC
Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative
Owner:NYCOMED GMBH
Pterin analogs
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.
Owner:BIOMARIN PHARMA INC
Blocking induction of tetrahydrobioterin to block induction of nitric oxide synthesis
InactiveUS6153615AReduce inhibitionRestore sensitivityBiocidePeptide/protein ingredientsSide effectTreatment effect
Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and / or pterin salvage pathway tetrahydrobiopterin synthesis antagonists are administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylactic or curative effect for endotoxin- or cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension). The tetrahydrobiopterin synthesis antagonist may be administered with alpha 1-adrenergic agonist or with nitric oxide synthase inhibitor. The tetrahydrobiopterin synthesis antagonists are also administered to attenuate inflammation caused by induced nitric oxide production in immune cells. Unwanted counterproductive or side effects can be eliminated or ameliorated by administration additionally of levodopa with or without carbidopa and L-5-hydroxytryptophane.
Owner:CORNELL RES FOUNDATION INC
Ricin inhibitors and methods for use thereof
Ricin A-chain is an N-glycosidase that attacks ribosomal RNA at a highly conserved adenine residue. Crystallographic studies show that not only adenine and formycin, but also pterin-based rings can bind in the ricin active site. For a better understanding of the recognition mode between ricin, and adenine-like rings, the interaction energies and geometries were calculated for a number of complexes. Shiga toxin, a compound essentially identical to the protein originally isolated from Shigella dysenteriae, has an active protein chain that is a homologue of the ricin active chain, and catalyzes the same depurination reaction. The present invention is drawn to identifying inhibitors of ricin and Shiga toxin, using methods molecular mechanics and ab initio methods and using the identified inhibitors as antidotes to ricin or Shiga toxin, or to facilitate immunotoxin treatment by controlling non-specific cytotoxicity.
Owner:RES DEVMENT FOUND
Active oxygen scavengers containing pterin derivatives
PCT No. PCT / JP97 / 02649 Sec. 371 Date Mar. 31, 1998 Sec. 102(e) Date Mar. 31, 1998 PCT Filed Jul. 30, 1997 PCT Pub. No. WO98 / 04558 PCT Pub. Date May 2, 1998An active oxygen scavenger comprising as an active ingredient a pterin derivative of the formula (I): wherein R1 and R2 are independently a hydrogen atom, an alkyl group of 1 to 4 carbon atoms, or an acyl group of the formula R3-CO-, R3 is an alkyl group of 1 to 4 carbon atoms, X is a formyl group or hydroxymethyl group, A is a group of the formula (Ia): and n is 0 or an integer of 1 or more, with the proviso that when X is a hydroxymethyl group, n is 0, or when n is an integer of 1 or more, each of R1 and R2 is a hydrogen atoms, and X is a formyl group, or a cyclic compound thereof, or a salt thereof is disclosed.
Owner:CMIC
Process for production of biopterin compound
The present invention provides a transformed cell which is transformed by at least one gene of enzymes participating in biosynthesis of tetrahydrobiopterin and a process for the production of a biopterin compound using the same. In accordance with the present invention, the biopterin compound can be produced in large quantities in an industrial advantageous manner from less expensive materials.
Owner:ASUBIO PHARMA
Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
ActiveUS20110111436A1Disease diagnosisGlycinamide Ribonucleotide FormyltransferaseThymidylate synthase
Sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaaminopterin is assessed and patients are selected for treatment of cancer with 10-propargyl-10-deazaaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the amount of the selected polypeptide expressed by a reference cancer. The polypeptide includes a member of a folate pathway polypeptide within a cell and may include at least one of reduced folate carrier-1 enzyme (RFC-1), dihydrofolate reductase (DHFR), folylpoly-gamma-glutamate synthetase (FPGS), thymidylate synthase (TS), γ-glutamyl hydrolase (GGH), and glycinamide ribonucleotide formyltransferase (GARFT).
Owner:SLOAN KETTERING INST FOR CANCER RES
Microorganisms for efficient production of melatonin and related compounds
Recombinant microbial cells and methods for producing 5HTP, melatonin and related compounds using such cells are described. More specifically, the recombinant microbial cell may comprise exogenous genes encoding one or more of an L-tryptophan hydroxylase, a 5-hydroxy-L-tryptophan decarboxylyase, a serotonin acetyltransferase, an acetylserotonin O-methyltransferase; and means for providing tetrahydrobiopterin (THB), and can be further genetically modified to enrich one or more of tryptophan, S-adenosyl-L-methinonine and acetyl coenzyme A. Related sequences and vectors for use in preparing such recombinant microbial cells are also described.
Owner:DANMARKS TEKNISKE UNIV
Process for the reduction of pterins
The inventive process for the reduction of pterins by means of an alkali metal boron hydride in water to the corresponding 5,6,7,8-tetrahydropterins is characterized in that the reduction is carried out in the presence of a catalytical amount of a water-soluble Pb(II)-salt.
Owner:CERBIOS PHARMA
Stable compositions of tetrahydrobiopterin
The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.
Owner:DIPHARMA SA
Method for Producing Biopterins Using Tetrahydrobiopterin Biosynthesis Enzyme
InactiveUS20090104668A1Efficient productionIncrease productionSugar derivativesBacteriaEscherichia coliBiopterin
Biopterins are useful compounds utilized in pharmaceutical agents or functional foods. The presence of sepiapterin reductase (SPR) involved in the biosynthesis of biopterins has not been confirmed so far in microorganisms except for a few microorganisms such as blue-green algae. For efficiently producing biopterins using microorganisms, it has been demanded to obtain and use SPR genes derived from microorganisms. The present inventors have found that when Saccharomyces cerevisiae or Escherichia coli is transformed with a YIR035C gene from Saccharomyces cerevisiae or a yueD gene from Bacillus subtilis, the transformed microorganism secretes biopterins into a culture solution. Based on this finding, the present invention provides a polypeptide, DNA encoding the polypeptide, a recombinant vector comprising the DNA, and a transformant obtained by transformation with the vector, which are useful in biopterin production using microorganisms. Moreover, the present invention provides a method for efficiently producing biopterins using the transformant.
Owner:KANEKA CORP
Polymorphs of sepiapterin and salts thereof
ActiveUS11072614B2Diminishment of extentImprove clinical outcomesOrganic active ingredientsNervous disorderDiseasePterin
Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria.
Owner:PTC THERAPEUTICS MP INC
Pharmaceutical compositions comprising sepiapterin and uses thereof
PendingUS20200061070A1Improve propertiesImprove bioavailabilityPowder deliveryOrganic active ingredientsDiseasePterin
The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and / or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.
Owner:PTC THERAPEUTICS MP INC
Pharmaceutically acceptable salts of sepiapterin
PendingUS20210269443A1Improved propertyImprove bioavailabilityOrganic active ingredientsNervous disorderPharmaceutical drugPterin
The present invention relates to new pharmaceutical salts and / or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts and / or co-crystals of sepiapterin, as well as methods of treating tetrahydrobiopterin-related disorders including administration of a sepiapterin salt and / or co-crystal of the invention to a subject in need thereof.
Owner:PTC THERAPEUTICS MP INC
Process for production of biopterin compound
The present invention provides a transformed cell which is transformed by at least one gene of enzymes participating in biosynthesis of tetrahydrobiopterin and a process for the production of a biopterin compound using the same. In accordance with the present invention, the biopterin compound can be produced in large quantities in an industrial advantageous manner from less expensive materials.
Owner:ASUBIO PHARMA
Preparation method of L-erythro biopterin compound
ActiveCN112390800AReduce usageReduce pollutionOrganic chemistryMetabolism disorderBiochemical engineeringChemical compound
The invention relates to a preparation method of an L-erythro biopterin compound, wherein the L-erythro biopterin compound has a structure as shown in a formula (I), and the L-erythro biopterin compound as shown in the formula (I) is mainly prepared from a compound with a structure as shown in a formula (II) or a formula (III) through a dihydroxylation reaction. The preparation method of the L-erythro biopterin compound is high in production efficiency, low in cost, green, environmentally friendly and suitable for industrial production.
Owner:SHANGHAI FOREFRONT PHARMA CO LTD
Intermediate for preparing L-red biopterin compound and preparation method thereof
PendingCN114075234AReduce the difficulty of separationSuitable for industrial productionGroup 3/13 element organic compoundsOptically-active compound separationBiochemical engineeringChemical compound
The invention relates to an intermediate for preparing an L-red biopterincompound and a preparation method thereof, wherein the intermediate has a structure shown as a formula (IVa-1), a formula (IVa-2), a formula (IVa-3) or a formula (IVa-4), and the formulas (IVa-1), (IVa-2), (IVa-3) and (IVa-4) are defined in the specification. According to the invention, the intermediate and the preparation method thereof effectively realize the effects of one-pot resolution and purification, are simple and convenient to operate, can greatly reduce the production cost, and are particularly suitable for preparing L-red biopterin compounds.
Owner:SHANGHAI FOREFRONT PHARMA CO LTD
Methylamino-pterin derivative with inhibiting nitric oxide synthetase function
InactiveCN1583746AAnti-cancer broad spectrumIncreased toxicityOrganic active ingredientsNervous disorderDiseaseSide effect
This invention relates to methylaminopterin derivatives with 4-amino structure modified, which inhibit effect of nitrogen monoxide synthetase and growth of tumors. They have wide anti-cancer spectrum and little toxic side effect so as to be used in preparation of medicines for tumors, cancers, arthritis and intestinal diseases as well as chemicals for birth control.
Owner:CHINA PHARM UNIV
Assay
InactiveUS20100311068A1Increase productionMicrobiological testing/measurementBiological material analysisPterinMyelomonocytic cell
The invention relates to process for in vitro prediction of a potentially allergenic substance wherein monocytes and / or macrophages and / or myelomonocytic cell lines are cultivated in the presence of the substance and interferon-γ, whereby productions of cytokines and / or neopterin are increased and measured. The allergic reaction may be estimated by measuring up regulated or down-regulated genes chosen from G1P2, OASL, IFIT1, TRIM22, IFI44L, MXI, RSAD2, IFIT3, IFITM1, IFIT2, C 33.28 HERV-H protein mRNA, IFITM3, XK, GPR15, MT1G, MT1B; MT1A, ADFP, IL8, MT1E, MT1F, MT1H, SLC30A1, SERPINB2, CD83, TncRNA or expression products from them are measured. The invention also relates to a reagent kit for use in the process comprising interferon-γ and reagents which recognise cytokines preferably each of IL-8 and neopterin and / or reagents such as probes recognising up-regulated or down-regulated genes.
Owner:BIOVATOR TECH
Pterin analogs
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.
Owner:BIOMARIN PHARMA INC
Composition, synthesis, and use of new substituted pyran and pterin compounds
The present invention relates to substituted pterin compounds, their synthesis and use. In particular, the present invention relates to a new precursor compound and its analogs for synthesizing a new substituted pterin compound and its analogs. These new compounds are particularly suitable for treating molybdenum cofactor deficiency.
Owner:DUQUESNE UNIVERSITY
Pterin analogs
Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.
Owner:BIOMARIN PHARMA INC
Application of exosome metabolite as bipolar affective disorder marker
The invention provides an application of an exosome metabolite as a bipolar affective disorder marker. Specifically, the invention provides application of a reagent material and / or instrument equipment for detecting the exosome metabolite level in a sample from an individual to be detected in preparation of a detection system for diagnosing the bipolar affective disorder disease risk, and the exosome metabolite comprises phosphoric acid, chenodeoxycholic acid, lysophosphatidylethanolamine 14:0, N-acetyl methionine, 13-oxo-9Z,11E-octadecadienoic acid, glycine, 1-naphthylacetic acid, 2-aminoethanesulfonic acid / taurine, D-2-aminobutyric acid, biopterin, glucosamine, lysophosphatidylcholine 18:0, lysophosphatidylethanolamine 18:0, lysophosphatidylcholine 20:1, and PAF C-16. According to the invention, positive help can be provided for pathogenesis of bipolar affective disorder and research of new targeted therapy means.
Owner:佛山市第三人民医院(佛山市精神卫生中心)
Biomarker and Method for Determining an Oxidative Stress Level
InactiveUS20130065265A1Bioreactor/fermenter combinationsBiological substance pretreatmentsOxidative stressBiomarker (petroleum)
The present invention relates to a biomarker and a method for determining an oxidative stress level in a biological sample, which employs co-factor-dependent oxidative stress parameters, as well as a kit adapted for carrying out such a method. In one aspect the co-factor is tetrahydrobiopterin.
Owner:BIOCRATES LIFE SCIENCES AG
Method for detecting content of impurity 6-formylpterin in folic acid
ActiveCN113125611AImprove quality controlImprove quality and safetyComponent separationFluorescencePterin
The invention provides a method for detecting the content of an impurity 6-formylpterin in folic acid. According to the method, Agi 1 entSB-CN is taken as a chromatographic column, after high performance liquid chromatography (HPLC) separation, a fluorescence detector is adopted to carry out qualitative and quantitative detection on the impurity 6-formylpterin in folic acid, and methodological verification is carried out. Experiments prove that the method can realize synchronous quantitative detection of trace photosensitive impurities 6-formylpterin and pterin 6-carboxylic acid in folic acid, and has the advantages of strong specificity, rapidness, high sensitivity, high accuracy and the like. The method for synchronously and quantitatively detecting the trace photosensitive impurities 6-formylpterin and pterin 6-carboxylic acid in the folic acid is established for the first time, and the quality control on the folic acid is facilitated, so that the quality and the medication safety of the folic acid bulk drug are improved.
Owner:北京斯利安药业有限公司
Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
ActiveUS20100168118A1BiocideMicrobiological testing/measurementGlycinamide Ribonucleotide FormyltransferaseThymidylate synthase
The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the amount of the selected polypeptide expressed by a reference cancer, wherein the polypeptide includes a member of folate pathways within cells and may include at least one of reduced folate carrier-1 enzyme (RFC-1), dihydrofolate reductase (DHFR), folylpoly-gamma-glutamate synthetase (FPGS), thymidylate synthase (TS), γ-glutamyl hydrolase (GGH), and glycinamide ribonucleotide formyltransferase (GARFT). The present invention also relates to the use of 10-propargyl-10-deazaminopterin in the treatment of multiple myeloma.
Owner:SLOAN KETTERING INST FOR CANCER RES
A body fluid pterin spectrum detection kit and its use
Owner:SHANGHAI IND TECH INST
Metabolic marker of medulloblastoma in urine and application thereof
The invention relates to a metabolic marker of medulloblastoma in urine and an application thereof. Specifically, the invention relates to an application of a reagent in preparing kits and / or chips for diagnosis and / or prognostic of medulloblastoma for detecting metabolites levels in urine of a subject. Metabolites are selected from one or more of the following matters: Uropterin, 20-oxo-leukotriene E4, Cortolone, Tetrahydrocortisone, [6]-Gingerdiol 3,5-diacetate, Pteroside Z, 12-oxo-2,3-dinor-10,15-phytodienoic acid, Melleolide M, Ethyl 7-epi-12-hydroxyjasmonate glucoside, Piperdial, Epishyobunone, 4R,5S,7R,11S)-11,12-Dihydroxy-1(10)-spirovetiven-2-one11-glucoside, PC-M5 and Acuminoside.
Owner:THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com